Epitopoietic Research Corporation (ERC-Worldwide), a biopharmaceutical company in the clinical stage, is developing a secure and highly efficient approach for treating cancer, specifically brain cancers and emerging infectious diseases like SARS-Cov-2, Ebola, and other viruses. ERC has established a network of prominent medical professionals in various countries globally, including the United States and Europe, to advance its immunotherapies from clinical development to the market. The therapeutic vaccines regimen developed by ERC has demonstrated early potential in patients with recurrent Glioblastoma multiforme (GBM), the most lethal form of brain cancer.
Epitopoietic Research
Headquarters
Belgium